While in the majority of these studies no subgroup analyses were performed according to tumor ER, Denkert and colleagues found that the pCR rate continuously rose with increased HER2 mRNA levels only in the ER-positive subgroup [12], which is in accordance with the notion that HER2-positive/ER-negative and HER2-positive/ER-positive tumors are different biological entities. Here, ERBB2 is linked to neoplasm.